Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2
מצבים רפואיים
Sickle Cell Disease
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Children's National Health System, Washington D.C., District of Columbia, United States
Contact: Study coordinator (Maryanne Odinakachukwu) · modinakach@childrensnational.org · 202-476-2957Contact: Principal Investigator (Robert Nickel, MD)Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Contact: Principal Investigator (Sonali Chaudhury, MD)Columbia University, New York, New York, United States
Contact: Principal Investigator (Monica Bhatia)Levine Children's Hospital, Charlotte, North Carolina, United States
Contact: Principal Investigator (Michael Kent, MD)Nationwide Children's Hospital, Columbus, Ohio, United States
Contact: Study coordinator (Hemalatha Rangarajan) · Hemalatha.Rangarajan@nationwidechildrens.org · 614-355-1689Contact: Principal Investigator (Hemalatha Rangarajan, MD)Alberta Children's Hospital, Calgary, Alberta, Canada
Contact: Study coordinator (Gregory Guilcher)Contact: Principal Investigator (Gregory Guilcher, MD)The Hospital for Sick Children, Toronto, Ontario, Canada
Contact: Principal Investigator (Muhammad Ali, MD)
מובילי המחקר
Robert Nickel, MD
Principal Investigator
Children's National Research Institute